PC
PCLOF.US Pharmacielo Ltd
- Market cap
- USD 5.20M
- P/E
- -
- P/B
- 13.98x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PCLOF.US undervalued?
Graham numberThe Graham number of Pharmacielo Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharmacielo Ltd fundamental analysis
No fundamental analysis for Pharmacielo Ltd yet.
Pharmacielo Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharmacielo Ltd
PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. It offers medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosm…
Full company profilePharmacielo Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharmacielo Ltd annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 787K | 2.65M | 1.94M | 5.31M | 1.54M | 3.48M | 2.60M | 4.22M |
| Gross Profit | -68.4K | -21.4K | -36.6K | -1.66M | -6.64M | -4.31M | 681K | -1.37M | 731K | 633K | 1.43M |
| Operating Income | -6.63M | -16.0K | -119K | -34.3M | -43.4M | -25.2M | -11.4M | -9.70M | -4.90M | -3.85M | -2.22M |
| EBITDA | -6.65M | -16.0K | -119K | -33.2M | -41.9M | -24.9M | -10.5M | -12.2M | -4.60M | -1.29M | -1.70M |
| Net Income | -11.3M | -16.0K | -144K | -34.7M | -43.8M | -26.6M | -14.5M | -16.3M | -9.14M | -3.98M | -5.48M |
| EPS | -0.22 | 0.00 | 0.00 | -0.36 | -0.39 | -0.18 | -0.10 | -0.10 | -0.05 | -0.02 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 14.6M | 104K | 208K | 50.2M | 44.0M | 36.0M | 25.1M | 22.3M | 18.4M | 8.56M | 12.8M |
| Total Liabilities | 2.15M | 12.6K | 22.7K | 4.73M | 17.8M | 16.6M | 18.7M | 24.0M | 25.9M | 23.9M | 23.5M |
| Shareholders' Equity | 12.5M | 91.0K | 186K | 45.5M | 26.2M | 19.3M | 6.39M | -1.68M | -7.52M | -15.3M | -10.7M |
| Cash & Short-term Investments | 5.11M | 87.1K | 208K | 13.8M | 9.61M | 5.63M | 326K | 62.2K | 148K | 289K | 77.5K |
| Total Debt | - | 0.00 | 0.00 | 1.57M | 4.47M | 8.43M | 12.6M | 18.3M | 20.5M | 18.6M | 18.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.04M | -19.9K | -78.5K | -25.2M | -22.6M | -20.1M | -9.88M | -5.15M | -1.97M | -881K | -7.94M |
| Capital Expenditure | 6.47M | 2.41M | 4.07M | 10.7M | 5.43M | 1.14M | 522K | 15.3K | 3.00 | 4.12 | 0.00 |
| Free Cash Flow | -10.5M | -19.9K | -4.14M | -36.0M | -28.0M | -21.2M | -10.4M | -5.17M | -1.97M | -881K | -7.94M |
| Ratios | |||||||||||
| ROE | -90.3% | -17.6% | -77.8% | -76.3% | -166.7% | -137.8% | -227.1% | - | - | - | - |
| ROA | -77.0% | -15.4% | -69.4% | -69.1% | -99.4% | -74.1% | -57.8% | -73.1% | -49.7% | -46.5% | -43.0% |
| Net Profit Margin | - | - | - | -4,405.6% | -1,648.7% | -1,369.1% | -273.5% | -1,057.1% | -262.7% | -153.0% | -129.8% |
| Debt to Equity | - | 0.00x | 0.00x | 0.03x | 0.17x | 0.44x | 1.97x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharmacielo Ltd dividends
Pharmacielo Ltd has not paid dividends in the last 9 fiscal years.
Who owns Pharmacielo Ltd
- Insiders 13.12%
- Institutions 0.14%
- Public & others 86.75%
- Shares outstanding 200M
- Free float 189M
Pharmacielo Ltd company profile
- Company name
- Pharmacielo Ltd
- Ticker
- PCLOF.US
- ISIN
- CA71716K1012
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 82 Richmond Street East, Toronto, ON, Canada, M5C 1P1
- Phone
- 416 315 8741
- Website
- pharmacielo.com
About Pharmacielo Ltd
PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. It offers medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Pharmacielo Ltd management
4- Mr. Marc Lustig M.B.A., M.Sc.Chairman & CEO · born 1974
- Mr. Ian D. Atacan B.Sc., C.M.A., C.P.A., M.B.A.CFO, Corporate Secretary & Director
- Mr. Andres Felipe BoteroChief Operating Officer
- Dr. Decio Rabelo de Castro FilhoChief Medical Officer